A. Bonebrake

发表

GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.

D. Alberts, R. Barakat, A. Hutson, 2018, Gynecologic oncology.

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

D. Bodurka, D. Miller, J. Schorge, 2008, Gynecologic oncology.

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Group study.

B. Monk, C. Aghajanian, P. Ramirez, 2017 .

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

B. Monk, A. Secord, J. Chan, 2022, Gynecologic oncology.

Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

F. Abdul-Karim, T. Radivoyevitch, J. Fanning, 2012, Journal of Translational Medicine.

GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).

D. Alberts, R. Barakat, A. Hutson, 2019, Gynecologic oncology.

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.

M. Birrer, K. Yonemori, A. Secord, 2022, Gynecologic oncology.

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

B. Monk, J. Chan, C. Aghajanian, 2017, Gynecologic oncology.

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

A. Stuckey, A. Secord, C. Aghajanian, 2018, Gynecologic oncology.

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

G. Anderson, A. Sood, J. Moon, 2014, European journal of cancer.

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

B. Monk, A. Secord, C. Aghajanian, 2018, Gynecologic oncology.

Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.

A. Covens, A. Bonebrake, D. Gersell, 2011, Gynecologic oncology.

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.

B. Monk, Joan L. Walker, R. Edwards, 2011, Gynecologic oncology.

Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

F. Abdul-Karim, T. Radivoyevitch, J. Fanning, 2012, Journal of Translational Medicine.

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

A. Godwin, A. Sood, H. Lankes, 2013, Gynecologic oncology.

Yolk sac tumor presenting as a colonic mass in a post-menopausal woman: A case report

A. Bonebrake, M. Greenwade, R. Short, 2022, Gynecologic oncology reports.

GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.

W. E. Richards, D. Alberts, R. Barakat, 2020, Gynecologic oncology.

GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients

W. E. Richards, R. Barakat, J. Kauderer, 2018, Gynecologic Oncology.

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.

D. Alberts, L. Ramondetta, L. Landrum, 2012, Gynecologic oncology.

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

B. Monk, J. Chan, C. Aghajanian, 2017, Gynecologic oncology.